Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 0.18% as of July 10, 2025, with mixed performance among constituent stocks [3] - Major gainers included Giant Bio (02367) up 4.24%, Yaoshi Bang (09885) up 4.13%, and Dongyangguang Changjiang Pharmaceutical (01558) up 3.48% [3] - The Hang Seng Healthcare ETF (513060) fell by 0.17%, with a latest price of 0.58 yuan, but saw a 2.48% increase over the past week [3] Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) announced measures to optimize lifecycle regulation to support high-end medical device innovation, particularly benefiting the in vitro diagnostics (IVD) industry [4] - Policies include accelerated approvals and international registration facilitation, which will enhance the global competitiveness of IVD companies [4] - The document from NMPA is expected to directly benefit the IVD sector, with domestic biochemical diagnostics largely free from foreign constraints [4] Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF recorded a financing buy-in of 220 million yuan and a financing balance of 267 million yuan [5] - Over the past two years, the ETF's net value increased by 20.23%, with a maximum monthly return of 28.34% and an average monthly return of 6.82% [5] - As of July 4, 2025, the ETF's one-year Sharpe ratio was 2.07, indicating strong risk-adjusted returns [5] Group 4: Valuation and Tracking - The Hang Seng Healthcare ETF has a current price-to-earnings ratio (PE-TTM) of 27.84, which is below the historical average, indicating a low valuation compared to the past three years [6] - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.069% over the past year [5][6] - The ETF's management fee is 0.50%, and the custody fee is 0.15%, contributing to its overall cost structure [5]

7月3日，新开源今日收盘17.09元，上涨1.12%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到26.91倍，总市值83.07亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入3.25亿元，同比-17.69%；净利润8042.03万元， 同比-33.75%，销售毛利率44.07%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新开源26.9123.752.2383.07亿行业平均 45.4652.833.8280.74亿行业中值41.1241.842.4143.80亿1正丹股份8.2110.483.91124.75亿2星湖科技 10.2512.671.42119.46亿3梅花生物10.5711.602.06317.80亿4嘉化能源11.0811.791.15118.86亿5聚合顺 11.4511.851.8435.60亿6万华化学14.3313.141.741713.05亿7雪峰科技14.7513.421.8089.70亿8浙江龙盛 14.9816.440.96333.79亿9宇新股份16.2814.261.0743.80亿10江南化工16.9216.951.5615 ...

证券简称：昭衍新药 证券代码：603127 公告编号：2025-026 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立基金 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、与专业投资机构合作参与投资设立产业基金情况概述 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于 2024 年 12 月 20 日召开第四届董事会第十一次会议，审议通过了《关于公司与专业投 资机构合作参与投资设立基金的议案》，同意公司或指定子公司以不超过 2,000 万人民币投资参与华夏致远创业投资基金（北京）合伙企业（有限合伙）（暂定 名）（以下简称"本基金"、"合伙企业"）的发起设立。华夏股权投资基金管 理（北京）有限公司为本基金的普通合伙人、执行事务合伙人，并担任本基金的 基金管理人。具体内容详见公司于 2024 年 12 月 21 日在上海证券交易所网站 （www.sse.com.cn）及指定信息披露媒体《上海证券报》披露的《昭衍新药关于 与专业投资机构合作参与投资设立基金的公告》（公告编号： ...

Core Insights - The event in Kobe, Japan, highlighted a strategic partnership between the Guangdong-Hong Kong-Macao Greater Bay Area and Japan's Kansai region, focusing on green energy and health industries [1][2] - The collaboration aims to integrate resources and innovation across various sectors, including offshore wind power, hydrogen energy, and smart medical devices [1][3] Group 1: Industry Collaboration - The meeting attracted 350 representatives from Chinese and Japanese enterprises, discussing cooperation in health technology, market expansion, and product innovation [2] - The Guangdong-Hong Kong-Macao Greater Bay Area is recognized for its high economic vitality and innovation-driven approach, leading to a new wave of industrial transformation [2][3] - The partnership emphasizes a "Japan technology + Bay Area intelligence" model, leveraging Japan's advanced medical technology and Guangdong's market potential [3][4] Group 2: Aging Population Solutions - Both regions face aging population challenges, with Japan having a well-established elder care system and Guangdong possessing advantages in AI healthcare and remote monitoring [5][4] - The collaboration aims to combine Japan's expertise in elder care with Guangdong's technological capabilities, creating new business opportunities [5][6] Group 3: Innovative Business Models - The event showcased a shift from traditional trade to innovative collaboration, with over 60% of discussions focused on joint research and technology licensing rather than simple trade [6][7] - The partnership is expected to enhance global competitiveness, with examples of successful integration of Japanese precision manufacturing in Guangdong's wind power equipment [6][7] Group 4: Investment Opportunities - Hong Kong is positioned as a regional headquarters for over 1,400 Japanese companies, facilitating connections to mainland innovation [7] - The Greater Bay Area's market size and high GDP per capita make it an attractive investment destination for Japanese enterprises [7][8]

央广网郑州6月27日消息（记者 郝振青）合规经营是企业发展的生命线。在河南省郑州经济技术开发 区，郑州安图生物工程股份有限公司（以下简称 "安图生物"）将"合规"植入进研发、生产、销售乃至 财务管理的每一个环节，实现从票据审核、费用报销到税务申报的全链条智能管控。 全链合规管控：助力企业高质量发展 "我们公司新人入职的'第一课'，便是通过模拟真实业务场景的报销流程实训、票据合规性实战演练， 让'合规意识'如同基因般融入每位员工的职业血脉。"安图生物相关负责人说，该公司的管理层将合规 决策纳入日常管理，每月召开的"合规决策情景模拟"，使每个流程都嵌入合规责任清单，让税务合规从 财务部门的"独角戏"变为全公司的"大合唱"。 作为体外诊断行业领军企业，安图生物始终将供应商合规管理视为激活产业链高质量发展的核心引擎。 从供应商的资质准入、纳税信用审查，到生产运营、质量管控等综合维度，安图生物均设置了严苛的筛 选标准。凭借这套科学严谨的体系，安图生物不仅保障了自身供应链的安全稳定，更通过 "以点带面" 的方式，引导上下游企业共同增强合规意识。 "严格的供应商信用管理既是供应链保障，更是行业合规发展的引擎。"安图生物采购 ...

| 大信会计师事务所 WUYIGE Certified | | | | | | Public | | Accountants | LLP. | | 电话 | Telephone： | +86 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | （10）82330558 | | | | | | | | | | | | | | | 北京市海淀区知春路 1 号 Room2206 22/F,Xueyuan | | | | | | | | International | | Tower | | 传真 Fax： | | | +86（10）82327668 | | | | | | | | | | | | | | | 学院国际大厦 22 层 2206 No.1 ZhichunRoad,Haidian | | | | | | | Dist. | | | | 网址 | Internet： | | | www.daxincpa.com.cn | | | | | | | | | | | | | | | 10 ...

Core Viewpoint - Antu Biology's investment dispute with Mobidiag has concluded with a settlement agreement, leading to the dissolution of their joint venture, Antu Mobidiag [1][3]. Group 1: Investment History - In December 2018, Antu Biology signed a joint venture agreement with Mobidiag to establish a company in China, with Antu investing €8 million for a 65% stake and Mobidiag investing €4.3 million for a 35% stake [1]. - Antu Mobidiag was primarily engaged in the research, sales, and after-sales services of molecular diagnostic products [1]. Group 2: Arbitration Process - In April 2024, Antu Biology filed for arbitration with the ICC due to disagreements over the joint venture and licensing agreements, following Mobidiag's unilateral termination of the agreements in November 2021 [2]. - The arbitration case was settled amicably before a hearing, resulting in a settlement agreement where Mobidiag will pay Antu Biology $10 million [3]. Group 3: Financial Performance - Antu Biology reported a revenue of 4.471 billion yuan for 2024, a year-on-year increase of 27.5468 million yuan, representing a growth of 0.62% [3]. - The net profit attributable to the parent company was 1.194 billion yuan, a decrease of 22.987 million yuan, reflecting a decline of 1.89% compared to the previous year [3]. - Antu Mobidiag has been operating at a loss, with net profits of -44.9566 million yuan for 2024 and -3.291 million yuan for the first quarter of 2025 [4]. Group 4: Impact of Dissolution - The dissolution of Antu Mobidiag is in accordance with the settlement agreement and will not materially affect Antu Biology's overall business development or profitability [4].

上海科华生物工程股份有限公司的主营业务是体外诊断试剂、医疗检验仪器的研发、生产和销售。公司 的主要产品是生化诊断、免疫诊断、生化免疫诊断自动化、分子诊断、质谱、POCT（胶体金）、代 理。国家科技进步二等奖、国家高新技术企业、国家知识产权试点企业、国家发改委生物医学工程高技 术产业化示范企业、陕西省和西安市创新型企业、陕西省生命科学检测仪器工程技术研究中心依托单位 等荣誉。 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入3.88亿元，同比-12.50%；净利润-53259784.78 元，同比-84.79%，销售毛利率37.39%。 6月3日，科华生物今日收盘6.13元，上涨2.51%，最新市净率0.97，创17天以来新低，总市值31.53亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)29科华生物-4.74-4.920.9731.53亿行业平均 50.8049.074.67108.36亿行业中值36.7136.842.4850.19亿1天益医疗-1758.71-3012.481.8822.41亿2澳华内 镜-655.90328.975.2569.12亿3诺唯赞-427.6 ...

Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents and medical testing instruments [1] - The latest financial report for Q1 2025 shows a revenue of 388 million yuan, a year-on-year decrease of 12.50%, and a net profit of -53.26 million yuan, a year-on-year decrease of 84.79% [1] - The company has a current market capitalization of 3.06 billion yuan and a price-to-book ratio of 0.94 [1] Group 2 - The company has received several honors, including the National Science and Technology Progress Award and recognition as a National High-tech Enterprise [1] - As of the latest report, five institutions hold shares in the company, with a total holding of 114.66 million shares valued at 649 million yuan [1] - The company's gross profit margin stands at 37.39% [1] Group 3 - The company's PE (TTM) is -4.60, while the industry average PE is 48.81 [2] - The company is compared to other firms in the industry, with varying PE ratios and market capitalizations [2] - The industry median price-to-book ratio is 2.40, while the company's is 0.94 [2]

导读： 布鲁克公司发布2025年Q1财报，营收增长11.0%，核心业务BSI表现强劲，但对全年持谨慎态度，受美国研究经费削减等影响，预计营收冲击1亿美元。 公司计划通过成本控制等措施缓解压力。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在全球科研与经济环境充满不确定性的背景下，Br u k e r（布鲁克）于近日发布了2 0 2 5年第一季度财报，展现出韧性与增长并存的稳健表现。 数据显示 2 0 2 5年Q1实现营收 8 . 0 1 4亿美元 ，比2 0 2 4年Q1的7 . 2 1 7亿美元 增长了11 . 0% 。本季度营收有机增长为2 . 9%，按固定汇率（CER） 计算的营收增长为1 2 . 5%。其中，来自收购的营收增长为9 . 6%，外汇换算则带来1 . 5个百分点的负面影响。 Bruke r 的 核 心 业 务 板 块 —— 科 学 仪 器 （ BSI ） 在 本 季 度 表 现 尤 为 强 劲 ， 营 收 达 7 . 4 4 5 亿 美 元 ， 同 比 增 长 1 4 . 3% ， 有 机 营 收 增 长 5 . 1 ...